KPTI
Karyopharm Therapeutics Inc
0.645$
-0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2.5% | 4.6% | 6.0% | 3.6% | 3.4% | 4.4% | 4.3% | 2.8% | 4.8% | 4.4% | 3.9% | 3.2% | 4.1% | |
| 97.5% | 95.4% | 94.0% | 96.4% | 96.6% | 95.6% | 95.7% | 97.2% | 95.2% | 95.6% | 96.1% | 96.8% | 95.9% | |
| 98.7% | 116.5% | 106.7% | 89.5% | 93.2% | 109.0% | 115.3% | 86.4% | 69.3% | 81.2% | 96.3% | 89.6% | 83.2% | |
| 85.5% | 90.9% | 89.2% | 72.6% | 71.2% | 89.0% | 91.1% | 75.1% | 60.4% | 66.8% | 76.1% | 77.5% | 69.6% | |
| 184.3% | 207.4% | 195.9% | 162.1% | 164.4% | 198.1% | 206.5% | 161.5% | 129.8% | 148.0% | 172.4% | 164.1% | 152.0% | |
| -86.8% | -112.0% | -101.9% | -65.7% | -67.8% | -102.4% | -110.8% | -64.3% | -34.6% | -52.4% | -76.3% | -67.4% | -56.2% | |
| 16.9% | 18.4% | 17.8% | 20.9% | 29.4% | 36.7% | 36.6% | 29.6% | 25.0% | 37.0% | 35.8% | 39.3% | 33.6% | |
| -95.8% | -123.6% | -112.6% | 55.8% | -82.6% | -101.1% | -78.0% | -98.1% | -75.1% | -300.1% | -63.9% | -200.5% | -153.3% | |
| 0.0% | 0.4% | 0.2% | 0.2% | 0.1% | -0.4% | 0.1% | 0.1% | 0.1% | -0.2% | 0.0% | – | – | |
| -95.8% | -124.0% | -112.8% | 55.6% | -82.7% | -100.8% | -78.2% | -98.2% | -75.2% | -299.9% | -63.9% | -200.5% | -153.3% | |
| -78.7% | -105.0% | -94.6% | 76.9% | -53.1% | -64.2% | -41.2% | -68.3% | -51.1% | -263.0% | -28.0% | -161.2% | -119.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.